Immunome Inc.: management transactions · United States · SEC (Form 4)

About Immunome Inc.

Immunome Inc. (ticker: IMNM) is a U.S.-based biotechnology company listed on the Nasdaq market in the United States, focused on targeted oncology rather than commercial-stage drug sales. Headquartered in Bothell, Washington, Immunome is building a precision-oncology platform designed to develop first-in-class and best-in-class therapies for patients with significant unmet medical need. The company’s value proposition is centered on research, clinical development, and pipeline expansion, making it a development-stage biotech with meaningful pipeline optionality but also execution risk. Immunome was originally incorporated in 2006 and later converted into a Delaware corporation in 2015. Since then, it has broadened its scientific capabilities through internal research and business-development transactions. A notable part of its credibility comes from the leadership team’s experience in designing, developing, manufacturing, and commercializing targeted cancer therapies, including antibody-drug conjugates (ADCs). That background is strategically relevant because the company is pursuing a modality-led oncology strategy in a highly competitive field. The current pipeline is anchored by several programs. Varegacestat, formerly AL102, is an oral gamma-secretase inhibitor in late-stage clinical development for desmoid tumors. IM-1021 is a ROR1-targeted ADC currently in Phase 1. IM-3050 is a FAP-targeted radioligand program that has received IND clearance. In addition, Immunome is advancing preclinical ADC candidates including IM-1617, IM-1340, and IM-1335, all aimed at solid tumors. This pipeline mix shows a company trying to balance nearer-term clinical catalysts with longer-duration discovery assets. From a competitive standpoint, Immunome operates in a crowded oncology landscape dominated by large pharmaceutical companies and specialized biotechnology peers. Its differentiation lies in scientific focus, target selection, and modality expertise rather than scale. The company’s emphasis on ADCs and other targeted approaches is intended to improve efficacy while potentially reducing off-target toxicity, a key theme in modern cancer drug development. Recent news has been particularly important for the equity story. In 2025, Immunome announced positive Phase 3 top-line results for varegacestat in desmoid tumors, supporting a planned NDA filing in the second quarter of 2026. Management also highlighted ongoing Phase 1 work for IM-1021, with initial data expected in 2026, and plans for multiple IND submissions across its ADC portfolio during 2026. The company also raised substantial capital in late 2025, extending its projected cash runway into 2028. For investors in the U.S. Nasdaq-listed name IMNM, the key focus remains clinical execution, regulatory milestones, and financing discipline.